Hemophilia News Today

2 weeks ago | hemophilianewstoday.com | Marisa Wexler

Jivi (damoctocog alfa pegol) has received approval from the U.S. Food and Drug Administration (FDA) that now extends to children with hemophilia A as young as 7 years old. Jivi had previously been authorized for hemophilia A patients 12 and older.

3 weeks ago | hemophilianewstoday.com | Margarida Maia

Prophylactic (preventive) treatment for hemophilia A and B is generally more effective than on-demand treatment in reducing the frequency of bleeding, but the benefit is not as clear in patients who have developed inhibitors that limit how well replacement clotting factors work. That’s according to real-world data from explorer6 (NCT03741881), a non-interventional study sponsored by Novo Nordisk that ran across 33 countries.

1 month ago | hemophilianewstoday.com | Patricia Inacio

A single-center U.S. study found relatively little genetic testing was done for girls with a 50% risk of being a hemophilia carrier — people with the altered gene who don’t have hemophilia themselves but can pass it to their children — over a four-year period in Washington state. Specifically, the testing — followed by genetic counseling — was conducted for about one-quarter of young girls offered such services at Seattle Children’s Hospital, according to the findings of the retrospective study.

1 month ago | hemophilianewstoday.com | Jennifer Lynne

I never used to think about aging because I was too focused on surviving the present: heavy periods, chronic anemia, and endless insurance hurdles. But lately, I’ve started to feel the shift. My joints take longer to recover. Mornings come with stiffness. Even the swelling from a minor finger bleed lingers for weeks. The truth is, I’m aging with hemophilia — and no one ever told me what that would look like.

1 month ago | hemophilianewstoday.com | Patricia Inacio

Children with severe hemophilia A with blood group O are not at increased risk of developing neutralizing antibodies against factor VIII (FVIII) replacement therapy, a study found. The study, “Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group,” was published in Haemophilia.